Haleon: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Alex Neman (bicara | kontrib) kTidak ada ringkasan suntingan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
| (17 revisi perantara oleh 7 pengguna tidak ditampilkan) | |||
Baris 1:
{{Expand language|topic=|langcode=en|otherarticle=Haleon|date=November 2024}}
{{Kembangkan|date=November 2024}}
{{Infobox company
| name = Haleon plc
Baris 9 ⟶ 12:
| traded_as = {{ubl|{{lse|HLN}}|{{nyse|HLN}}|[[FTSE 100]] component}}
| ISIN = GB00BMX86B70
| predecessor = GSK Consumer Healthcare<br/>Pfizer Consumer Healthcare
| area_served = Seluruh dunia
| key_people = {{plainlist|
Baris 26 ⟶ 29:
* [[Caltrate]]
* [[Centrum (multivitamin)|Centrum]]
* Contac
* [[Emergen-C]]
Baris 71 ⟶ 73:
Sir [[Dave Lewis (pengusaha)|David Lewis]] adalah [[ketua]], dengan Brian McNamara sebagai CEO.<ref name="haleonsky">{{Cite news|last=Kleinman|first=Mark|date=3 Mei 2022|title=GSK's £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks|url=https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875|work=[[Sky News]]|access-date=10 Juni 2022|archive-date=2023-02-11|archive-url=https://web.archive.org/web/20230211180519/https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875|dead-url=no}}</ref> Haleon terdaftar di [[Bursa Efek London|London Stock Exchange]] dan merupakan komponen dari [[Indeks FTSE 100|FTSE 100]], dengan listing sekunder di [[Bursa Efek New York|New York Stock Exchange]]. Penjualan tahunan berjumlah sekitar £10 miliar di 120 pasar pada tahun 2020.<ref name="forbes12">{{Cite news|last=Cornell|first=Joe|date=15 July 2021|title=GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022|url=https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0|work=[[Forbes]]|access-date=10 Juni 2022|archive-date=2023-02-11|archive-url=https://web.archive.org/web/20230211180517/https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0|dead-url=no}}</ref>
Di Indonesia, Haleon beroperasi di bawah dua
== Sejarah ==
Baris 80 ⟶ 82:
[[Unilever]] menawarkan £50 miliar untuk bisnis tersebut pada tahun 2022, dalam tawaran yang ditolak GSK.<ref name="guardian1">{{Cite news|last=Jolly|first=Jasper|date=19 Januari 2022|title=Unilever will not increase £50bn offer for GSK consumer arm|url=https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm|work=[[The Guardian]]|access-date=10 Juni 2022|archive-date=2022-10-18|archive-url=https://web.archive.org/web/20221018002210/https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm|dead-url=no}}</ref> [[Nestlé]] mengkaji kemungkinan penawaran bersama dengan [[Reckitt Benckiser|Reckitt]].<ref name="bloomberg1">{{Cite news|date=25 Mei 2022|title=Nestle Eyed Biggest-Ever Deal in Aborted Move for GSK Unit|url=https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg|work=[[Bloomberg News]]|access-date=10 Juni 2022|archive-date=2023-04-30|archive-url=https://web.archive.org/web/20230430142405/https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg|dead-url=no}}</ref>
Usulan spin-off merek perawatan bibir [[ChapStick]] senilai $600 juta diperdebatkan pada tahun 2023.<ref name="bloomberg2">{{Cite news|last=Tse|first=Crystal|last2=Nair|first2=Dinesh|last3=David|first3=Ruth|date=24 Februari 2023|title=GSK Spinoff Haleon Explores Potential $600 Million Sale of ChapStick Brand|url=https://archive.
== Operasi==
Baris 156 ⟶ 158:
* [[Synthol (mouthwash)|Synthol]] (kesehatan mulut)
* Theraflu (Pernafasan)
* Triaminic
* [[Tums|Tum]] (pencernaan)
* Viva (vitamin dan natural), asal: [[Nepal]]
| |||